Understanding the consequences of miR-145 reintroduction in human breast cancer (BC) could reveal its tumor-suppressive functions and may disclose new aspects of BC biology. Therefore, we characterized the effects of miR-145 re-expression in BC cell lines by using proliferation and apoptosis assays. As a result, we found that miR-145 exhibited a pro-apoptotic effect, which is dependent on TP53 activation, and that TP53 activation can, in turn, stimulate miR-145 expression, thus establishing a deathpromoting loop between miR-145 and TP53. We also found that miR-145 can downregulate estrogen receptor-a (ER-a) protein expression through direct interaction with two complementary sites within its coding sequence. In conclusion, we described a tumor suppression function of miR-145 in BC cell lines, and we linked miR-145 to TP53 and ER-a. Moreover, our findings support a view that miR-145 re-expression therapy could be mainly envisioned in the specific group of patients with ER-a-positive and/or TP53 wild-type tumors.
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Although the overall survival rate for BC is increasing, an effective therapy for it has yet to be found. To meet this need, a better understanding of BC biology is required.
MicroRNAs (miRNAs) are short (19-24 nucleotides) noncoding RNAs that are generated from longer transcripts (primiRNA and pre-miRNA) in sequential maturation steps. 2 The main known function of miRNAs is the regulation of gene expression at the post-transcriptional level either by protein translation inhibition or messenger RNA (mRNA) degradation through binding to imperfect sequence homology sites of target mRNAs and recruitment of the RNA-induced silencing complex (RISC). 3 miRNAs are involved in fundamental processes, such as embryonic development and cell differentiation, 4 in which fine regulation of gene expression in time and space is required for the correct execution of these processes. Consequently, the fact that researchers have found alterations of miRNA expression in many human diseases, including cancer, 5 is not surprising. In fact, all human tumors analyzed so far have abnormalities in miRNA expression, and studies have identified signatures of deregulated miRNAs in different tumors. 6, 7 miR-145 is one of the miRNAs whose expression is most commonly reduced in various human cancers, including BC, 8 colon 9 and lung 10 cancers. In particular, the role of miR-145 in BC merits special attention, because several lines of evidence have shown that miR-145 expression is inversely correlated with BC tumor grade, 11 tumor size 11 and Ki-67 proliferation index. 8 Researchers previously studied the function of miR-145 in colon and cervical cancer cells 12, 13 and found miR-145 targets, such as insulin receptor substrate 1 (IRS-1) in colon cancer cells, 14 homeobox A9 (HOXA9) in immortalized bone marrow cells, 15 and octamer-binding transcription factor 4 (OCT4), sex determining region Y box 2 (SOX2) and Kruppellike factor 4 (KLF4) in human embryonic stem cells. 16 However, to our knowledge, no authors have reported on the effects of miR-145 re-expression in BC cells. Discovering the functions of miR-145 in BC may disclose new aspects of BC biology that can eventually generate new therapeutic approaches. Therefore, the purpose of our study was to investigate the effects of miR-145 reintroduction and identify new miR-145 targets in BC. Our strategy consisted in the use of proliferation and apoptosis assays after transfection of miR-145. As a result, we characterized the molecular pathways involved in miR-145-dependent apoptosis and identified new targets of miR-145 in BC cell lines. Finally, we found that the status of molecular markers, such as estrogen receptor-a (ER-a) and TP53, predicted the BC response to miR-145 reintroduction.
Results miR-145 impairs cell proliferation in BC cell lines through apoptosis. We previously showed that miR-145 expression levels were consistently lower in primary human breast tumors and BC cell lines than in normal breast tissues. 8 Herein, we extended these findings by measuring miR-145 expression levels in 14 breast tumors and in 10 BC cell lines using quantitative real-time PCR (qRT-PCR). As a result, we found lower expression of miR-145 in breast tumors (13-fold) and BC cell lines (150-to 700-fold) than in normal breast tissues ( Supplementary Figures 1a and b) .
To study the effects of miR-145 re-expression in BC cell lines, we first carried out an in vitro proliferation assay using tetrazolium staining (MTT assay) on six BC cell lines after transfection with a synthetic miR-145 precursor (Ambion, Austin, TX, USA). Four cell lines (MCF-7, CAMA-1, MCF-10A and T47D) showed a significant reduction in cell number, whereas the remaining two (MDA-MB-231 and MDA-MB-436) exhibited no effect on cell number after miR-145 transfection (Figure 1a) . To further confirm the specificity of miR-145 effects, we transfected scalar amounts of this miRNA in MCF-7 and MDA-MB-231 cells and assessed proliferation by MTT assay. MCF-7 cells had a dose-dependent response to miR-145, whereas MDA-MB-231 cells did not have any significant response (Figure 1b) . We assayed the transfection efficiency of miR-145 in these cell lines using qRT-PCR, and we 42 For TP53, À indicates no expression, þ /À low expression, þ medium expression, þ þ high expression, mut mutated and wt wild type. For ER-a, protein levels are indicated as þ (positive) or -(negative). (b) Assessment of cell number by tetrazolium staining (MTT assay) of MCF-7 and MDA-MB-231 cell lines transfected with scalar amounts of miR-145 and scrambled (from 100 nM to 3.125 nM). The cells were counted 48 h after miR-145 and scrambled transfection. For each concentration, miR-145 effect was expressed as a relative value (fold change, Y axis) to scrambled control. The symbol asterisk represents a significant difference (Po0.05) compared with scrambled by t-test. Null cells were treated only with lipofectamine miR-145 and TP53 participate in a death-promoting loop in BC R Spizzo et al confirmed a similar fold increase of miR-145 expression both in MCF-7 and in MDA-MB-231 (Supplementary Figures 3a) . Interestingly, these experiments suggested that the antiproliferative effect of miR-145 was occurring in cells expressing wild-type (wt) TP53 or ER-a.
The anti-proliferative effect that we observed after miR-145 re-expression in BC cell lines can be explained by an increase of cell death (that is, apoptosis) and/or a reduction of the number of cells that are cycling. First, we determined whether miR-145 effect on BC cell number was a result of apoptosis induction. Therefore, we analyzed early apoptotic events, such as exposure of phosphatidylserine outside the cellular membrane, by annexin V and propidium iodide (PI) staining of living cells. After transfection with miR-145, we observed higher levels of early apoptotic cells (annexin V-positive and PI-negative) in CAMA-1 (up to six times) and in MCF-7 (up to three times) compared with scrambled control, whereas, we did not observe any effect in MDA-MB-231 cells (Figure 2a) . Furthermore, the analysis of caspase-3/7 activity and PARP cleavage after miR-145 transfection showed an induction of apoptosis in CAMA-1, MCF-7 and MCF-10A, but not in MDA-MB-231 (Figures 2b-e; Supplementary Figures  2a and b) .
Then, we determined whether miR-145 effects on BC cell proliferation were a result of changes in cell cycle distribution. Specifically, we assessed cell cycle phases in MCF-10A, MCF-7 and MDA-MB-231 cells by PI staining coupled with FACS analysis 24, 48 and 72 h after transfection with miR-145. As a result, we did not observe any consistent changes in the cell cycle profile of BC cell transfected with miR-145 cells versus cells transfected with scrambled control, except for an increase in the percentage of cells in sub-G1 phase, which is an indirect sign of apoptosis (Supplementary Figure 2c) .
Taken together, these results indicated that miR-145 reintroduction reduced the number of BC cells by inducing apoptosis in cells either expressing wt TP53 or ER-a. miR-145 activates TP53 pathway. As we observed that miR-145 inhibited cell growth in TP53 wt cell lines, we hypothesized that this effect may depend on TP53 activation. To verify this, first, we tested whether miR-145 induced the expression of TP53 transcriptional targets, such as p53 upregulated modulator of apoptosis (PUMA) 17 and cyclindependent kinase inhibitor 1A (CDKN1A/P21), which is an inhibitor of cell cycle progression. 18 Therefore, we transfected miR-145 and scrambled control in MCF-7 in TP53 wt MCF-7, and 24 h later, we measured mRNA levels of PUMA and P21. As a result, we observed higher levels (up to three times) of PUMA and P21 mRNA after miR-145 transfection compared with scrambled control in MCF-7. Instead, neither PUMA nor P21 increased after miR-145 transfection in TP53-mutated MDA-MB-231 (Figure 3a) . At the same time, we observed an increase in TP53-acetylated levels and PUMA protein expression and a slight decrease in total TP53 and p21 protein expression after miR-145 transfection in MCF-10A (Figure 3b ). To confirm a dosedependent increase in PUMA protein expression after miR-145 expression, we also transfected scalar amounts of this miRNA in MCF-10A (Supplementary Figure 3b) . At the same time, to verify whether miR-145 induction of PUMA and P21 mRNA was dependent on TP53, we co-transfected miR-145 and small interfering RNA (siRNA) targeting TP53 in MCF-10A (TP53 wt), and 24 h later, we measured mRNA levels of PUMA and P21. This experiment confirmed the induction of PUMA and P21 mRNA after miR-145 transfection in MCF-10A compared with scrambled control (Figure 3c ), and most importantly it showed that this effect was completely impaired if TP53 was silenced during miR-145 reintroduction ( Figure 3c ).
To verify that BC cell growth inhibition after miR-145 transfection was dependent on TP53-mediated transactivation of PUMA, we tested the hypothesis whether inhibition of TP53 or PUMA expression by siRNA was able to reduce the anti-growth effect of miR-145. Therefore, we co-transfected MCF-7 cells with miR-145 and siRNAs targeting TP53 or PUMA, or with miR-145 alone. Twenty-four hours later, we observed a 20% increase in the number of cells when we transfected miR-145 together with siRNA against PUMA or against TP53 versus when we transfected miR-145 alone ( Figure 3d ).
Furthermore, Sachdeva et al. 19 recently reported that TP53 can activate miR-145 transcription in a colon cancer cell model. To confirm that TP53 induces miR-145 expression in our BC model as well, we treated TP53 wt MCF-10A and TP53-mutated MDA-MB-231 cells with two different TP53-activating drugs, that is, Adriamycin (1.72 mM) and Nutlin-3 (10 mM), and 24 h later, we measured miR-145 expression levels by qRT-PCR. We also measured miR-34c expression levels, and we used it as positive control, because He et al. 20 previously proved that TP53 transactivates miR-34c transcription. After TP53 activation with both Adriamycin or Nutlin-3 treatment, we observed an increase in miR-145 and miR-34c levels in TP53 wt MCF-10A cells, whereas neither miR-34c nor miR-145 increased in TP53-mutated MDA-MB-2321 cells ( Figure 4 ).
Taken together, the miR-145-dependent activation of TP53 and PUMA and the TP53-dependent transactivation of miR-145 expression showed the existence of a death-promoting loop between miR-145 and TP53 in BC cells. 
miR-145 and measured ER-a protein expression levels by western blotting. As a result, we detected consistent reduction in ER-a protein expression 48 h after miR-145 transfection, which was also evident after transfection of scalar amounts of miR-145 (75% lower than in scrambled control) (Figure 5a -c and Supplementary Figure 4) . We also Figure 4 TP53 induces miR-145 expression levels. (a and b) miR-145 and miR-34c levels were measured by qRT-PCR 24 h after treatment with Adriamycin and Nutlin-3, respectively. Fold changes of miR-145 and miR-34c have been calculated using 2 -DCt method. U6 mRNA levels were used as an internal normalization control. Values represent average and bars represent S.D. of three independent experiments. At the bottom of the graph, western blotting of TP53 protein levels is shown to prove induction of TP53 protein levels after Adriamycin and Nutlin-3 treatment. GAPDH and b-actin protein levels were used as loading controls. The asterisk represents a significant difference (Po0.05) compared with untreated samples by t-test miR-145 and TP53 participate in a death-promoting loop in BC R Spizzo et al evaluated cyclin D1 protein expression, a downstream target of ER-a, and we detected a parallel reduction in cyclin D1 levels (Figure 5a-b; Supplementary Figure 4) . The decrease in ER-a and cyclin D1 protein levels was also confirmed by reverse-phase proteomic array (data not shown). Next, we sought to clarify how miR-145 reduced ER-a protein expression in BC cells. We tested whether miR-145 regulated ER-a expression at the post-transcriptional level by directly targeting ER-a mRNA (ESR-1). 2 Hence, we interrogated miRNA target prediction programs for miR-145 target sites in the 3 0 UTR of ESR1 mRNA (Pictar, 21 Miranda, 22 Diana-microT 23 and TargetScan 24 ), and we also interrogated the RNA22 prediction program 25 for miR-145 target sites in the full-length sequence of ESR1 mRNA. Five putative miR-145-binding sites were predicted, three located inside the coding sequence (CDS) of ESR1 and two in the 3 0 UTR of ESR1 (Figure 5d, Supplementary Table 1 (Figure 5d ). In parallel, we generated pGL3-mutated constructs by deleting the predicted target sites of miR-145 in ESR1 (Supplementary Table 1 ). Two out of the five sites, named target #2 and #3 in Figure 5d , caused a significant reduction in luciferase activity in MCF-7 after miR-145 re-expression compared with scrambled control; at the same time, these two sites did not cause a significant decrease in luciferase activity when their mutated version was used (Figure 5d ). Both of these target sites were located in the CDS of ESR1 and have a 5 0 seed region of perfect complementarity (Supplementary Table 1 ).
Previous studies showed that miRNAs could regulate mRNA expression by inhibiting mRNA translation or by inducing mRNA degradation. Moreover, authors proved that the luciferase assay that we used (Figure 5d) is not useful to discriminate how miRNAs repress their targets (that is, inhibition of mRNA translation or degradation of mRNA). 26 Therefore, to understand how miR-145 decreases ER-a protein expression, we measured ESR1 mRNA expression levels in the same samples in which we previously observed a reduction in ER-a protein expression levels after miR-145 transfection ( Figure 5a) . As a result, we observed an increase in ESR1 mRNA expression after miR-145 transfection (Figure 6a ). Although all of the evidences that we have collected so far suggested that miR-145 directly targeted ESR1 only by inhibition of protein translation, still we sought to exclude the possibility that miR-145 could indirectly reduce ER-a protein expression by reducing ER-a protein stability. To measure ER-a stability, we used western blotting to quantify the phosphorylation of ER-a at serine 118 (ER-a-pS118), which is known to inhibit proteosomal degradation of ER-a, 27 and we expressed stability as the ratio of ER-a-pS118 to total ER-a. The ER-a-pS118/total ER-a ratio was even higher in MCF7 cells after treatment with miR-145 than with scrambled control (Figure 6b ). Therefore, we ruled out an indirect effect of miR-145 on ER-a protein stability. In conclusion, these data indicated that miR-145 inhibited ER-a protein expression exclusively by repressing ESR1 mRNA translation through interaction with two target sites within the ESR1 CDS.
Discussion
Our findings indicated that miR-145 inhibited proliferation and induced apoptosis of BC cells through activation of the TP53 pathway and reduction in ER-a expression. To the best of our knowledge, we are the first to describe a tumor-suppressor function of miR-145 in BC cells and to directly link miR-145 with ER-a and TP53, both of which have important roles in breast tumor biology. 28, 29 Previous studies showed the anti-proliferative properties of miR-145 in colon cancer cell models and reported various targets. For example, miR-145 could inhibit the growth of HCT-116 colon cancer cells through the targeting of IRS-1.
14 As HCT116 colon cancer cells carry a wt TP53 gene, it is possible that the activation of TP53 could have also been involved in the observed miR-145 effect in these cells. However, apoptosis may not be the only response to miR-145 upregulation. For example, it has been recently shown that miR-145 is low in self-renewing human embryonic stem cells and increases during differentiation. In these cells, miR-145 may facilitate differentiation by repressing the core pluripotency factors, OCT4, SOX2 and KLF4, thereby silencing the self-renewal program. 16 Therefore, it seems plausible that miR-145 function may depend on different target genes that are operating in specific cell types. At the same time, a general mechanism appears to be the activation of TP53, and this mechanism would lead to apoptosis in wt TP53 cancer cells. Hence, similarly to TP53 loss, the loss of miR-145 expression in most human tumors and cancer cell lines may provide a favorable environment for cell survival.
Our results indicated that miR-145 activated TP53 toward a prevalent apoptosis response more than toward a cell cycle arrest response. In fact, we observed an almost unique increase in PUMA protein levels instead of p21 protein levels after miR-145 transfection. Further study is needed to determine how miR-145 activates TP53, in other words, identify the miR-145 target(s) responsible for TP53 activation.
Besides showing that miR-145 activated TP53 pathway, we also found that TP53 itself induced miR-145 transcription in BC cells. It was previously reported that TP53 activates miR-145 transcription during starvation in a colon cancer cell line. 19 Here, we showed that two drugs (that is, the MDM-2 inhibitor Nutlin-3 and the DNA-damage inducer Adriamycin) that activate the TP53 pathway increased miR-145 expression, and we also showed that this effect was missing in TP53-mutated MDA-MB-231 BC cell line. Thus, we conclude that a positive regulatory loop between miR-145 and TP53 exists, which leads to apoptotic death in cancer cells carrying a wt TP53 gene. The existence of regulatory loops between miRNAs and transcription factors was previously reported. 30 For example, E2F1, E2F2 and E2F3 directly bind the promoter of the miR-17-92 cluster, activating its transcription, and miR-20a, a member of the miR-17-92 cluster, modulates the translation of the E2F2 and E2F3 mRNAs, 31 and this negative feed back regulatory loop probably protects cells from apoptosis caused by excessive E2F expression. Furthermore, transcription of miR-34 family is regulated by TP53 32 and miR-34a itself has been shown to regulate TP53 activity. Fold changes of ESR1 mRNA levels were calculated using 2 -DCt method. GAPDH mRNA levels were used as an internal normalization control. Fold changes of ER-a pS118/ER-a ratios were calculated by western blotting (see Figure 5a) . The asterisk represents a significant difference (Po0.05) compared with scrambled by t-test. Null cells were treated only with lipofectamine miR-145 and TP53 participate in a death-promoting loop in BC R Spizzo et al
Previous studies described a direct correlation of miR-145 with ER-a-positive tumor status 11, 34 and an inverse correlation of it with the Ki-67 proliferation index. 8 The inverse correlation of miR-145 with Ki-67 agrees with the anti-proliferative effect of miR-145 that we describe herein, whereas the direct correlation of miR-145 with ER-a expression is unexpected and more difficult to explain. It is possible that, as the expression of miR-145 was associated with cell differentiation, 16 this direct correlation may be linked to the higher grade of differentiation associated with ER-a-positive BCs. Different groups have identified other miRNAs that directly target ESR1 (for example, miR-221, miR-222 and miR-206).
35,36 Kondo et al. 37 described an inverse correlation between the levels of miR-206 and the ER-a protein status of the tumors. At the same time, authors described a direct correlation of miR-221/ miR-222 with ER-a protein status of the tumors. 34 The direct correlations of miR-145 and miR-221/miR-222 with ER-a status are puzzling and contradictory and need further work.
It is noted that miR-145 is located in the 5q33.1 region of human genome and clusters with miR-143. In colon cancer cell lines, Akao et al. 38 showed that both miR-143 and miR-145 impaired cell growth. Moreover, expression of both miR-145 and miR-143 is commonly reduced in several types of tumors. 8, 39 Using Rapid Amplification of cDNA Ends (RACE), we were able to clone a single cDNA fragment containing both of these miRNAs (Supplementary Figure 5a) (GenBank accession number GQ292874). However, in the BC cell lines that we used in this study, expression of miR-143 was much lower than that of miR-145 (10-to 100-fold) (data not shown), making difficult to obtain consistent results regarding miR-143 regulation by TP53. Nevertheless, the common reduction in miR-143 and miR-145 expression in BC tumor samples and the common transcription of the two microRNAs ( Supplementary  Figure 5b) both suggest that miR-143 may have a tumorsuppressor function in BC, as miR-145 does.
In conclusion, miR-145 tumor-suppressor effect occurs through promotion of apoptosis in both ER-a-positive and wt TP53-expressing BC cells. miR-145 expression activates TP53 and suppresses ER-a, whereas TP53 activates miR-145, representing a positive regulatory death loop that may open the avenue for miR-145 re-expression therapy in particular in the specific group of BC patients carrying ER-a-positive and/or wt TP53 tumors.
Materials and Methods
Cell lines and patient samples. MCF-7, CAMA-1, MDA-MB-231, MCF-10A, T47D and MDA-MB-436 were obtained from the American Type Culture Collection (ATCC) (Manassas, VA, USA) and cultured according to the ATCC protocols. Normal breast tissue and breast tumor samples were collected in the University of Ferrara and processed as described previously. 8 miRNA precursor molecules and siRNAs. Synthetic miRNA precursor molecules and negative control #1 (scrambled) were purchased form Ambion. These synthetic oligos were dissolved in nuclease-free water to a stock concentration of 50 mM. siRNAs against TP53 and PUMA were purchased from Dharmacon (Chicago, IL, USA). If not otherwise specified, miR-145 and scrambled were used at 100 nM concentration.
Hormones and drugs. Nutlin-3 was purchased from Cayman Chemical (Ann Arbor, MI, USA) and dissolved in dimethyl sulfoxide to a stock solution of 2 mM. Adriamycin was kindly provided by Dr. Waldemar Priebe (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) and resuspended in water to a final concentration of 0.5 mM.
RNA isolation and qRT-PCR. Purification of total RNA using TRIzol reagent (Invitrogen, Carlsband, CA, USA) was carried out as described previously. 8 miR-145 and RNU6B probes (Applied Biosystems, Foster City, CA, USA) were used for mature miRNA quantification according the manufacturer's protocol. Five hundred nanograms of total RNA was used for the retrotranscription step. The 2 -DCt method was used to calculate the relative abundance of miR-145 compared with RNU6Bexpression. 40 To generate total cDNAs for protein-coding gene expression, 1 mg of total RNA was retrotranscribed using SuperScript II (Invitrogen) with random hexamers according to the manufacturer's protocol. Real-time PCR analysis of the samples was carried out with iQ SYBR Green Supermix (Bio-Rad, Hercules, CA, USA). The list of primers that we used herein is shown in Supplementary Table 1 .
Protein isolation, western blotting and antibodies. Breast cancer cell were collected from 6-well plates using trypsin-ethylenediaminetetraacetic acid (EDTA) (Mediatech, Manassas, VA, USA) and dissolved in NP40 lysis buffer (0.5% NP40, 250 mM NaCl, 50 mM Hepes, 5 mM ethylenediaminetetraacetic acid, 0.5 mM egtazic acid) freshly supplemented with a complete protease inhibitor and phosphatase inhibitor cocktails 1 and 2 (Roche, Indianapolis, IN, USA). Proteins were purified as described previously. 41 The complete list of antibodies is described in Supplementary Table 3 .
In vitro proliferation assay. Breast cancer cells were plated in 96-well plates at a density of 10 000 cells/well. Transfection of the cells with either an miR-145 precursor molecule or a negative-control molecule (scrambled) at a final concentration of 100 nM was carried out using a Lipofectamine 2000 protocol (Invitrogen). Cells were also treated with Lipofectamine only (null cells). Both treatment and controls were performed in quadruplicate each time. Four hours after transfection (time 0), the absorbance of cells was estimated using a colorimetric MTT assay (CellTiter 96 AQueous One Solution; Promega, Madison, WI, USA), and this procedure was repeated every 24 h for 4 consecutive days.
Apoptotic assays. The number of early apoptotic of BC cells after miR-145 transfection was determined using an annexin V staining kit (BD Pharmingen, San Jose, CA, USA). Every 24 h, the cells were collected from 6-well plates, and annexin V staining of the cells was carried out according to the manufacturer's protocol. The cells were counterstained with PI and immediately read using a FACSCalibur system (BD, Franklin Lakes, NJ, USA). Only annexin V-positive and PI-negative cells were counted at each time point. For further confirmation of apoptosis, MCF7 cells were analyzed using the caspase-3/7 assay according to the manufacturer's protocol (Promega).
Cell cycle analysis. MCF7, MCF10A and MDA-MB-231 BC cell lines were seeded in 6-well plates and transfected with miR-145, scrambled control and with lipofectamine only (null). Every 24 h, the cells were collected from 6-well plate using trypsin-EDTA acid and washed twice with cold PBS. The cells were finally stained with PI solution containing RNase enzyme at 371C for 30 min. The stained cells were read using a FACSCalibur system (BD), and the gates for sub-G1, G1, S and G2 were arbitrary chosen by the operator.
miR-145-TP53 loop identification. MCF7 cells were seeded into 24-well plates at a concentration of 75 Â 10 3 cells/well in an antibiotic-free medium. Transfection of the cells was carried out with an miR-145 precursor molecule (Ambion), a negative-control molecule (scrambled) (Ambion), siRNA-PUMA (Dharmacon) and siRNA-p53 (Dharmacon) at a final concentration of 100 nM using Lipofectamine 2000 reagent (Invitrogen). Forty-eight hours after transfection, the cells were collected by trypsin-EDTA and were counted using a hemocytometer chamber.
Luciferase assay. Primer pairs were designed to amplify a region of about 200-300 bp around every predicted miR-145 target site within the ESR1 CDS and 3 0 UTR (Supplementary Table 2 ). The five amplicons (three in the CDS, two in the 3 0 UTR) were first mutated by sequence specific mutagenesis (Stratagene, La Jolla, CA, USA), and then both wt and mutated (mut) amplicons were cloned in pGL3 vector as described previously. 41 MCF7 cells (0.2 Â 10 6 ) were plated on 24-well plates; on the day after, the cells were transfected with miR-145 or scrambled miR-145 and TP53 participate in a death-promoting loop in BCcontrol (10 nM), with each pGL3 ESR1 construct (wt and mut) (0.4 mg/well), and with pRLTK vector (0.05 mg/well). Twenty-four hours afterward, the cells were rinsed with phosphate-buffered saline and dissolved in 1 Â Passive Lysis Buffer (Promega). Subsequently, the luciferase activity was measured using dual luciferase kit (Promega) using a Veritas luminometer (Turner Biosystems, Sunnyvale, CA, USA). Each combination of pGL3 (wt and mut) and pRLTK was tested in quadruplicate in three independent experiments.
Statistical analysis. The t-test was used to compare mean values in groups of samples (for example, miRNA expression data, number of proliferating cells). All reported P-values were calculated for groups with unequal variance using the Excel software program (Microsoft, Redmond, WA, USA). Po0.05 was considered significant.
